bigbio/sem_eval_2024_task_2

---
language:
- en
bigbio_language:
- English
multilinguality: monolingual
pretty_name: SemEval 2024 Task 2
homepage: https://allenai.org/data/scitail
bigbio_pubmed: false
bigbio_public: true
bigbio_tasks:
- TEXTUAL_ENTAILMENT
---

# Dataset Card for SemEval 2024 Task 2

## Dataset Description

- **Homepage:** https://sites.google.com/view/nli4ct/semeval-2024?authuser=0
- **Pubmed:** False
- **Public:** True
- **Tasks:** TE

## Dataset
(Description copied from dataset homepage)

The statements and evidence are generated by clinical domain experts, clinical trial organisers, and research oncologists from the Cancer Research UK Manchester Institute and the Digital Experimental Cancer Medicine Team. There are a total of (TBD) statements split evenly across the different sections and classes.
## Description
Each Clinical Trial Report (CTR) consists of 4 sections:
Eligibility criteria - A set of conditions for patients to be allowed to take part in the clinical trial
Intervention - Information concerning the type, dosage, frequency, and duration of treatments being studied.
Results - Number of participants in the trial, outcome measures, units, and the results.
Adverse events - These are signs and symptoms observed in patients during the clinical trial.
For this task, each CTR may contain 1-2 patient groups, called cohorts or arms. These groups may receive different treatments, or have different baseline characteristics.

## Citation Information

```
@article{,
author = {},
title = {},
journal = {},
volume = {},
year = {},
url = {},
doi = {},
biburl = {},
bibsource = {}
}

原始信息汇总

数据集卡片 for SemEval 2024 Task 2

数据集描述

• 主页: https://sites.google.com/view/nli4ct/semeval-2024?authuser=0
• Pubmed: False
• 公开: True
• 任务: TE

数据集

(描述从数据集主页复制)

声明和证据由临床领域专家、临床试验组织者和来自英国癌症研究曼彻斯特研究所和数字实验癌症医学团队的肿瘤学家生成。总共有（待定）个声明，均匀分布在不同的部分和类别中。

描述

每个临床试验报告（CTR）包含4个部分：

• 入选标准 - 患者被允许参加临床试验的一组条件
• 干预措施 - 有关正在研究的治疗类型、剂量、频率和持续时间的信息
• 结果 - 试验中的参与者数量、结果测量、单位和结果
• 不良事件 - 这些是在临床试验期间在患者身上观察到的体征和症状

对于此任务，每个CTR可能包含1-2个患者组，称为队列或臂。这些组可能接受不同的治疗，或有不同的基线特征。